Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
CRANBURY, N.J., Feb. 13, 2018 -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY on Wednesday, February 14, 2018 at 3:00pm ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The lead program in the Amicus portfolio is migalastat, an oral precision medicine for people living with Fabry disease who have amenable genetic mutations. Migalastat is currently approved under the trade name Galafold™ in the European Union, with additional approvals granted and pending in several geographies. The lead biologics program in the Amicus pipeline is ATB200/AT2221, a novel, late-stage, potential best-in-class treatment paradigm for Pompe disease. The Company is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
[email protected]
(609) 662-5044
Media:
Pure Communications
Jennifer Paganelli
[email protected]
(347) 658-8290
FOLD–G
